DocMorris AG (SWX:DOCM)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
7.39
-0.09 (-1.14%)
Jun 4, 2026, 5:06 PM CET
Market Cap359.89M +229.1%
Revenue (ttm)1.12B +10.6%
Net Income-134.40M
EPS-3.47
Shares Out 48.15M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume230,349
Open7.34
Previous Close7.48
Day's Range6.99 - 7.57
52-Week Range3.92 - 8.78
Beta1.88
AnalystsHold
Price Target7.49 (+1.35%)
Earnings DateAug 19, 2026

About DocMorris AG

DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally. The company offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional health care services to doctors, pharmacies, insurers, and health institutions. It sells its products to online mail-order pharmacies, and private individuals under the DocMorris, PromoFarma ... [Read more]

Sector Healthcare
Founded 1993
Employees 1,576
Stock Exchange SIX Swiss Exchange
Ticker Symbol DOCM
Full Company Profile

Financial Performance

In 2025, DocMorris AG's revenue was 1.12 billion, an increase of 10.56% compared to the previous year's 1.02 billion. Losses were -134.40 million, 38.2% more than in 2024.

Financial Statements

Analyst Summary

According to 9 analysts, the average rating for DOCM stock is "Hold." The 12-month stock price target is CHF 7.49, which is an increase of 1.35% from the latest price.

Price Target
CHF 7.49
(1.35% upside)
Analyst Consensus: Hold
Stock Forecasts

News

DocMorris AG Earnings Call Transcript: Q1 2026

Revenue grew 10.7% year-over-year, led by 30.4% Rx and 63.1% digital services growth. Adjusted EBITDA improved by CHF 9.8 million to CHF -6.3 million, with breakeven targeted in 2026. Guidance for revenue and EBITDA is confirmed, with strong momentum in all key segments.

7 weeks ago - Transcripts

DocMorris AG Earnings release: Q1 2026

DocMorris AG released its Q1 2026 earnings on April 16, 2026, summarizing the period's financial results.

7 weeks ago - Filings

DocMorris AG Slides: Q1 2026

DocMorris AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 16, 2026.

7 weeks ago - Filings

DocMorris price target lowered to CHF 4.45 from CHF 8.10 at Berenberg

Berenberg lowered the firm’s price target on DocMorris (ZRSEF) to CHF 4.45 from CHF 8.10 and keeps a Hold rating on the shares.

2 months ago - TheFly

DocMorris price target lowered to CHF 4.50 from CHF 7 at Deutsche Bank

Deutsche Bank lowered the firm’s price target on DocMorris (ZRSEF) to CHF 4.50 from CHF 7 and keeps a Hold rating on the shares.

2 months ago - TheFly

DocMorris AG Earnings Call Transcript: H2 2025

Revenue grew 11.1% in 2025, driven by Rx (+33%) and digital services (+110%), with strong margin gains and a robust liquidity position. EBITDA breakeven is targeted for 2026, supported by platform expansion, cost control, and a new Google partnership.

2 months ago - Transcripts

DocMorris AG Annual report: H2 2025

DocMorris AG has published its H2 2025 annual report on March 19, 2026.

2 months ago - Filings

DocMorris AG Slides: H2 2025

DocMorris AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 19, 2026.

2 months ago - Filings

DocMorris AG Earnings release: Q4 2025

DocMorris AG released its Q4 2025 earnings on January 20, 2026, summarizing the period's financial results.

4 months ago - Filings

DocMorris AG Earnings release: Q3 2025

DocMorris AG released its Q3 2025 earnings on October 16, 2025, summarizing the period's financial results.

8 months ago - Filings

DocMorris AG Earnings Call Transcript: H1 2025

Strong Rx and TeleClinic growth drove a 10.2% revenue increase in H1 2025, with gross margin up 70 bps and a solid balance sheet after a CHF 200 million capital raise. Full-year guidance is confirmed, with sequential EBITDA improvement expected as marketing spend is optimized.

10 months ago - Transcripts

DocMorris AG Quarterly report: H1 2025

DocMorris AG has published its H1 2025 quarterly earnings report on August 19, 2025.

10 months ago - Filings

DocMorris AG Slides: H1 2025

DocMorris AG has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 19, 2025.

10 months ago - Filings

Online drug retailer DocMorris meets expectations as cost savings help

Swiss online drug retailer DocMorris met expectations on Thursday as it released its full-year results for 2023, helped by structural cost savings.

2 years ago - Reuters

Online drug retailer DocMorris trims top end of 2023 outlook

Swiss online drug retailer DocMorris on Thursday narrowed down the higher end of its annual core loss forecast, citing weaker development in the paper prescription business.

2 years ago - Reuters